Description
PALLD has been only recently described in association with cancer predisposition and the risks are not well understood. This variant is denoted PALLD c.3250G>C at the cDNA level, p.Val1084Leu (V1084L) at the protein level, and results in the change of a Valine to a Leucine (GTG>CTG). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. PALLD Val1084Leu was not observed at a significant allele frequency in the NHLBI Exome Sequencing Project. Since Valine and Leucine share similar properties, this is considered a conservative amino acid substitution and is unlikely to affect protein integrity. PALLD Val1084Leu occurs at a position that is well conserved across species and is located in the Ig-like C2-type 3 domain (UniProt). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. On a molecular level, the impact of this missense variant on protein structure and function is not known and thus we consider this to be a variant of uncertain significance. Furthermore, based on the currently available information, cancer risks associated with this variant, and the PALLD gene, remain unclear.
# | Sample | Method | Observation |
---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences |
---|
1 | germline | yes | not provided | not provided | not provided | | not provided | not provided | not provided | not provided |